Akèy › Limfòm selil B › North Carolina
Etid klinik pou Limfòm selil B nan North Carolina
11 etid pou Limfòm selil B ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Atrium Health Levine Cancer Institute (Lci), Charlotte
- Duke University, Durham
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Charlotte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Charlotte
- Research Site, Charlotte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
- Levine Cancer Institute, Atrium Health, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT06792734BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- Atrium Health Levine Cancer Institute - Morehead, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.